Clinical and laboratory data for COVID-19 patients
| . | All patients (N = 113) . | DAT-positive patients (n = 52) . | DAT-negative patients (n = 61) . | P* . |
|---|---|---|---|---|
| Age, mean ± SD, y | 63.5 ± 17.1 | 65.2 ± 16.2 | 62.1 ± 17.9 | .17 |
| Males, n (%) | 60 (53.1) | 29 (55.8) | 31 (50.8) | .60 |
| Length of hospital stay, d | 15.5 (10-26) | 19 (10.2-30) | 14 (9-22.2) | .06 |
| Hemoglobin, g/L | 11.2 (8.6-12.7) | 9.8 (7.9-11.7) | 12.2 (9.4-13.1) | .001 |
| Red cell distribution width, % | 14 (13.2-15.2) | 14.5 (13.5-15.9) | 13.6 (12.7-14.4) | .001 |
| Platelet count, ×109/L | 260 (183-335) | 308 (207-395) | 237 (162-303) | .06 |
| Mean platelet volume, fL | 10.7 (10.1-11.5) | 10.6 (9.9-11.5) | 10.9 (10.1-11.5) | .82 |
| LDH, U/L | 229 (199.5-343.5) | 247 (203.5-351) | 227.5 (184.5-316) | .39 |
| Total bilirubin, mg/dL | 0.51 (0.32-0.71) | 0.52 (0.36-0.80) | 0.48 (0.33-0.66) | .63 |
| Serum ferritin, µg/L | 782 (452-1227) | 922 (526-1320.5) | 702 (359.5-1142.7) | .24 |
| D-dimer, µg/L | 1269 (711-2427) | 1578 (803.5-3338.5) | 1109 (635-2074.5) | .11 |
| C-reactive protein, mg/dL | 4.13 (1.42-10.32) | 6.27 (1.81-10.79) | 2.83 (1.12-9.11) | .12 |
| Patients receiving ≥1 transfusion, n (%) | 44 (39) | 27 (51.9) | 17 (27.9) | .009 |
| Units of RBCs transfused per patient, n | 0 (0-2) | 1 (0-2) | 0 (0-1) | .005 |
| Patients on endotracheal intubation, n (%) | 18 (16) | 11 (22) | 7 (11.5) | .13 |
| Mortality at 30 d, n (%)† | 14 (12.4) | 8 (15.4) | 6 (9.8) | .37 |
| . | All patients (N = 113) . | DAT-positive patients (n = 52) . | DAT-negative patients (n = 61) . | P* . |
|---|---|---|---|---|
| Age, mean ± SD, y | 63.5 ± 17.1 | 65.2 ± 16.2 | 62.1 ± 17.9 | .17 |
| Males, n (%) | 60 (53.1) | 29 (55.8) | 31 (50.8) | .60 |
| Length of hospital stay, d | 15.5 (10-26) | 19 (10.2-30) | 14 (9-22.2) | .06 |
| Hemoglobin, g/L | 11.2 (8.6-12.7) | 9.8 (7.9-11.7) | 12.2 (9.4-13.1) | .001 |
| Red cell distribution width, % | 14 (13.2-15.2) | 14.5 (13.5-15.9) | 13.6 (12.7-14.4) | .001 |
| Platelet count, ×109/L | 260 (183-335) | 308 (207-395) | 237 (162-303) | .06 |
| Mean platelet volume, fL | 10.7 (10.1-11.5) | 10.6 (9.9-11.5) | 10.9 (10.1-11.5) | .82 |
| LDH, U/L | 229 (199.5-343.5) | 247 (203.5-351) | 227.5 (184.5-316) | .39 |
| Total bilirubin, mg/dL | 0.51 (0.32-0.71) | 0.52 (0.36-0.80) | 0.48 (0.33-0.66) | .63 |
| Serum ferritin, µg/L | 782 (452-1227) | 922 (526-1320.5) | 702 (359.5-1142.7) | .24 |
| D-dimer, µg/L | 1269 (711-2427) | 1578 (803.5-3338.5) | 1109 (635-2074.5) | .11 |
| C-reactive protein, mg/dL | 4.13 (1.42-10.32) | 6.27 (1.81-10.79) | 2.83 (1.12-9.11) | .12 |
| Patients receiving ≥1 transfusion, n (%) | 44 (39) | 27 (51.9) | 17 (27.9) | .009 |
| Units of RBCs transfused per patient, n | 0 (0-2) | 1 (0-2) | 0 (0-1) | .005 |
| Patients on endotracheal intubation, n (%) | 18 (16) | 11 (22) | 7 (11.5) | .13 |
| Mortality at 30 d, n (%)† | 14 (12.4) | 8 (15.4) | 6 (9.8) | .37 |
Unless otherwise noted, data are median (interquartile range). Data for transfusion requirements were calculated during follow-up after DAT determination. Reference laboratory values were as follows: red cell distribution width, 11.5% to 14.5%; mean platelet volume, 9.5 to 13.1 fL; LDH, 135 to 214 U/L; total bilirubin, 0.12 to 1.1 mg/dL; serum ferritin, 15 to 150 µg/L; D-dimer <500 µg/L; and C-reactive protein <0.5 mg/dL. Numbers in bold type indicate statistical significance.
A χ2 test was used for discrete variables, and a Student t test or a Wilcoxon-Mann-Whitney test was used for continuous variables. Data were compared by generalized linear model (unadjusted).
Mortality at 30 days was calculated from the date of DAT determination. Other data refer to the day of DAT determination.